HIV Treatment During Pregnancy With Long-Acting Injections
Part of Infections clinical trials.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and willing to give written consent for yourself and your infant
- You are 10 to 23 weeks pregnant with one baby (confirmed by ultrasound)
- You were diagnosed with HIV before this pregnancy and have an undetectable viral load (fewer than 50 copies/mL) in the past 28 days
- You have already received at least one dose of cabotegravir and rilpivirine injections and plan to continue them every 4 weeks
- You plan to deliver at a study hospital and stay in the area for follow-up visits
- Your blood counts and liver function are stable (specific lab values in normal or near-normal range)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people living with HIV who have undetectable viral loads to see how well a long-acting injectable medication (cabotegravir plus rilpivirine) works in real-world conditions. It may help understand if this injection-based treatment can reliably keep HIV controlled with fewer pills.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.